Search Results - "Takigawa, Kei"

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    Transition-Metal-Catalyzed Regioselective Alkylation of Indoles with Alcohols by Putra, Anggi Eka, Takigawa, Kei, Tanaka, Hatsuki, Ito, Yoshihiko, Oe, Yohei, Ohta, Tetsuo

    Published in European journal of organic chemistry (01-10-2013)
    “…The regioselective alkylation of indoles with alcohols as alkylating reagents was developed by using Pd/C or RuCl2(PPh3)3/DPEphos {DPEphos =…”
    Get full text
    Journal Article
  15. 15
  16. 16
  17. 17

    Methylosome protein 50 associates with the purinergic receptor P2X5 and is involved in osteoclast maturation by Kim, Hyunsoo, Walsh, Matthew C., Yu, Jiyeon, Laskoski, Paul, Takigawa, Kei, Takegahara, Noriko, Choi, Yongwon

    Published in FEBS letters (01-01-2020)
    “…Purinergic signaling plays important roles in bone. P2X5, a member of ligand‐gated ion channel receptors, has been demonstrated to regulate osteoclast…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Gastrointestinal toxicities of proteasome inhibitor therapy by Shah, Jay, Devalaraju, Samanthika, Baerman, Elliot, Lee, Irene Jeong-Ah, Takigawa, Kei, Machado, Antonio Pizuorno, Catinis, Christine, Shatila, Malek, Varatharajalu, Krishnavathana, Shafi, Mehnaz, Lee, Hans C., Strati, Paolo, Thomas, Anusha, Wang, Yinghong

    “…Purpose Proteasome inhibitors (PIs), which cause cell death via tumor suppressor and pro-apoptotic proteins, are integral to treatment of many hematologic…”
    Get full text
    Journal Article
  20. 20

    The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity by Shah, Jay, Caleb Urias Rivera, Andres, Lee, Irene Jeong-Ah, Takigawa, Kei, Mathew, Antony, Wu, Deanna, Lu, Eric, Shatila, Malek, Thomas, Anusha S, Zhang, Hao Chi, Altan, Mehmet, Zhao, Dan, Xiao, Qinghuan, Wang, Yinghong

    Published in American journal of clinical oncology (30-10-2024)
    “…Immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, have been approved to treat…”
    Get full text
    Journal Article